Clinical Trials

ELIAS Animal Health has developed a unique immunotherapy treatment protocol which may permit the dog’s immune system to attack its own cancer cells. ELIAS Cancer Immunotherapy (ECI®)—a vaccine-enhanced adoptive cell therapy—has demonstrated effectiveness in clinical trials in both canines and humans, while avoiding or minimizing the need for chemotherapy or radiation treatment.

Canine Osteosarcoma

Enrollment for the latest canine osteosarcoma clinical study (ECI-OSA-04) is now closed. Results will be available in 2024.

Find results of the pivotal study (ECI-OSA-01) here.

“The T cell expansion is a huge component that, to my knowledge, none of the other autologous products are even trying to replicate.”

Zachary Wright, DVM, DACVIM (Oncology)

VCA Animal Diagnostic Clinic